Pharmaceutical

Biocon and Handok link to commercialise Liraglutide in South Korea

Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.

May 25, 2024 - 04:00
Biocon and Handok link to commercialise Liraglutide in South Korea
Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea.
Read the original article

Tags:

Previous Article

EC approves Celltrion’s Omlyclo for allergic conditions

Next Article

Magazine: Lula’s progress plan for Brazil: a year on

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific

ESMO 2024: BMS cuts ties as Immatics regains full right...

Sep 18, 2024

STAT+: Early findings in gene therapy death suggest CRISPR was not the cause

STAT+: Early findings in gene therapy death suggest CRI...

Apr 27, 2023

U.S. life expectancy rose in 2022, but it remains below its pre-pandemic level

U.S. life expectancy rose in 2022, but it remains below...

Nov 29, 2023